Mannitol Dose Response Study in Cystic Fibrosis

Study Overview
=================
Brief Summary
-----------------
Many cystic fibrosis patients die of lung failure caused by repeated lung infections from thick, sticky mucus. Past studies have shown Bronchitol inhalation may help to facilitate the clearance of mucus by altering its rheology and replenishing the airway surface liquid layer in these patients, thereby enhancing the shift of stagnant mucus from the lungs. The study aim is to determine the optimal dose of mannitol to generate clinical improvement in patients with cystic fibrosis.

Official Title
-----------------
A Phase IIa Randomised, Open Label, Dose Response Study to Determine the Optimum Dose of Dry Powder Mannitol Required to Generate Clinical Improvement In Patients With Cystic Fibrosis

Conditions
-----------------
Cystic Fibrosis

Intervention / Treatment
-----------------
* Drug: mannitol
* Drug: mannitol
* Drug: mannitol
* Drug: mannitol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of cystic fibrosis (sweat test/genotype) 7 years or older FEV1 between 40% and 90% of predicted for height, age and gender. Able to perform acceptable-quality spirometry Clinically stable in the week up to study entry No additional antibiotics or additional oral steroids for a period of 14 days before study entry (routine antibiotics permitted) Exclusion Criteria Currently active asthma Subjects colonized with Burkholderia cepacia or MRSA Considered terminally ill or listed for transplantation Requiring home oxygen or assisted ventilation Concurrent illness that in the investigators opinion may contribute to an increased and unacceptable risk if the subject was enrolled in the study (e.g. significant varicies, portal hypertension, cor pulmonale) Significant episode of haemoptysis (>60 mLs) in the previous 12 months Heart attack or stroke in last 3 months Known aortic or cerebral aneurysm Subjects who are breast feeding or pregnant. At risk females unwilling to use appropriate contraception to prevent pregnancy during the course of the study Subjects who have participated in another investigative drug study parallel to, or within 4 weeks of study entry. Known intolerance to mannitol or unable to take any form of bronchodilator medications. Uncontrolled hypertension, systolic BP > 200 or diastolic BP> than 100 Concurrent use of beta blocker medication Concurrent use of hypertonic saline Canada: Concurrent use of other pharmacological mucolytic agents other than Pulmozyme Argentina: Concurrent use of other pharmacological mucolytic agents including Pulmozyme

Ages Eligible for Study
-----------------
Minimum Age: 7 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br> | Drug: mannitol<br>* 40 mg BD<br>|
| Active Comparator: 2<br> | Drug: mannitol<br>* 120mg BD<br>|
| Active Comparator: 3<br> | Drug: mannitol<br>* 240mg BD<br>|
| Active Comparator: 4<br> | Drug: mannitol<br>* 400mg BD<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| FEV1 |  | 2 weeks | 
| FVC |  | 2 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| other measures of lung function |  | various | 
| QOL |  | 2 weeks | 
| sputum microbiology |  | 2 weeks | 
| safety |  | 2 weeks | 
| sputum clearance and cough |  | 2 weeks | 
| respiratory symptoms |  | 2 weeks |